Management of methicillin-resistant Staphylococcus aureus bacteremia

被引:87
作者
Cosgrove, Sara E. [1 ]
Fowler, Vance G., Jr. [2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Johns Hopkins Med Inst, Baltimore, MD 21287 USA
[2] Duke Univ, Med Ctr, Durham, NC USA
基金
美国国家卫生研究院;
关键词
D O I
10.1086/533595
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Staphylococcus aureus bacteremia and endocarditis are serious infections that demand prompt clinical attention to ensure good outcomes. Of foremost importance is identifying and managing the source of infection and any associated complications. Evaluation for the presence of cardiac involvement is essential because inadequately managed S. aureus endocarditis is life threatening. Thus, physicians must aggressively negotiate treatment paths, considering whether the S. aureus bacteremia is complicated, whether foreign sources of infection should be removed or replaced, and whether surgical intervention is necessary. Selection of an antibiotic treatment is also an essential factor for optimal management. The increasing prevalence of methicillin-resistant S. aureus (MRSA) infections has created a tremendous demand for effective and safe antimicrobial agents other than the historic anti-MRSA agent vancomycin.
引用
收藏
页码:S386 / S393
页数:8
相关论文
共 72 条
[31]   SHORT-COURSE THERAPY OF CATHETER-RELATED STAPHYLOCOCCUS-AUREUS BACTEREMIA - A METAANALYSIS [J].
JERNIGAN, JA ;
FARR, BM .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (04) :304-311
[32]   Staphylococcus aureus prosthetic valve endocarditis:: Optimal management and risk factors for death [J].
John, MDV ;
Hibberd, PL ;
Karchmer, AW ;
Sleeper, LA ;
Calderwood, SB .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (06) :1302-1309
[33]   Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus [J].
Kaka, Anjum S. ;
Rueda, Adriana M. ;
Shelburne, Samuel A., III ;
Hulten, Kristina ;
Hamill, Richard J. ;
Musher, Daniel M. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (03) :680-683
[34]   Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia [J].
Khosrovaneh, A ;
Riederer, K ;
Saeed, S ;
Tabriz, MS ;
Shah, AR ;
Hanna, MM ;
Sharma, M ;
Johnson, LB ;
Fakih, MG ;
Khatib, R .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (09) :1328-1330
[35]   COMBINATION ANTIMICROBIAL THERAPY FOR STAPHYLOCOCCUS-AUREUS ENDOCARDITIS IN PATIENTS ADDICTED TO PARENTERAL DRUGS AND IN NON-ADDICTS - A PROSPECTIVE-STUDY [J].
KORZENIOWSKI, O ;
SANDE, MA .
ANNALS OF INTERNAL MEDICINE, 1982, 97 (04) :496-503
[36]   Telavancin: a novel lipoglycopeptide for serious Gram-positive infections [J].
Laohavaleeson, Somvadee ;
Kuti, Joseph L. ;
Nicolau, David P. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (03) :347-357
[37]   COURSE AND OUTCOME OF BACTEREMIA DUE TO STAPHYLOCOCCUS-AUREUS - EVALUATION OF DIFFERENT CLINICAL CASE DEFINITIONS [J].
LAUTENSCHLAGER, S ;
HERZOG, C ;
ZIMMERLI, W .
CLINICAL INFECTIOUS DISEASES, 1993, 16 (04) :567-573
[38]   SLOW RESPONSE TO VANCOMYCIN OR VANCOMYCIN PLUS RIFAMPIN IN METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS ENDOCARDITIS [J].
LEVINE, DP ;
FROMM, BS ;
REDDY, BR .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (09) :674-680
[39]   Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 μg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis [J].
Maclayton, Darego O. ;
Suda, Katie J. ;
Coval, Krista A. ;
York, Cynthia B. ;
Garey, Kevin W. .
CLINICAL THERAPEUTICS, 2006, 28 (08) :1208-1216
[40]   STAPHYLOCOCCUS-AUREUS CATHETER-ASSOCIATED BACTEREMIA - MINIMAL EFFECTIVE THERAPY AND UNUSUAL INFECTIOUS COMPLICATIONS ASSOCIATED WITH ARTERIAL SHEATH CATHETERS [J].
MALANOSKI, GJ ;
SAMORE, MH ;
PEFANIS, A ;
KARCHMER, AW .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (11) :1161-1166